Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Entera Bio Ltd (NQ: ENTX )

2.930 USD UNCHANGED
Streaming Delayed Price Updated: 6:03 AM EDT, Apr 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Entera Bio Ltd

< Previous 1 2 Next >
Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors
From GlobeNewswire News Releases
Entera Appoints Ramesh Ratan as Chief Financial Officer
From GlobeNewswire News Releases
New Data Suggest Entera’s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress
From GlobeNewswire News Releases
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
Refreshed board to bring fresh perspectives, relevant expertise and diverse experience 
From GlobeNewswire News Releases
Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020
From GlobeNewswire News Releases
Entera Bio to Report Financial Results for the Year Ended December 31, 2020 on March 18, 2021
From GlobeNewswire News Releases
Thinking about buying stock in Entera Bio, Atossa Therapeutics, Xpeng, Micron Technology, or Verizon?
InvestorsObserver issues critical PriceWatch Alerts for ENTX, ATOS, XPEV, MU, and VZ. 
From PR Newswire
Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data
From GlobeNewswire News Releases
Entera Bio To Present At The H.C. Wainwright Global Life Sciences Conference
From GlobeNewswire News Releases
Entera Bio Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research
From GlobeNewswire News Releases
Entera Bio Initiates New Research Program For Oral GLP-2
From GlobeNewswire News Releases
Entera Bio Issues Letter to Shareholders
From GlobeNewswire News Releases
Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis
EB613 Phase 2 Placebo-Controlled, Dose-Ranging Study Ongoing in Israel with Complete 3 Month Biomarker Data expected in Q1:21 and Final Bone Mineral Density, or BMD, Data Expected in Q2:21 
From GlobeNewswire News Releases
Entera Bio Appoints Spiros Jamas as Chief Executive Officer
From GlobeNewswire News Releases
Entera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update
From GlobeNewswire News Releases
Entera Bio to Report Third Quarter 2020 Business and Financial Results on November 19, 2020
From GlobeNewswire News Releases
Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis
From GlobeNewswire News Releases
Entera Bio to Present at the H.C. Wainwright 6th Annual Israel Conference
From GlobeNewswire News Releases
Entera Bio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
From GlobeNewswire News Releases
Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results
From GlobeNewswire News Releases
Entera Bio to Report Second Quarter 2020 Business and Financial Results on August 20, 2020
From GlobeNewswire News Releases
Entera Bio Announces Management Changes
From GlobeNewswire News Releases
Entera Bio to Present at BTIG’s Virtual Biotechnology Conference
From GlobeNewswire News Releases
Thinking about buying stock in Entera Bio, Immutep, Electrameccanica Vehicles, Delta Air Lines, or Carnival Corp?
InvestorsObserver issues critical PriceWatch Alerts for ENTX, IMMP, SOLO, DAL, and CCL. 
From PR Newswire
Entera Bio Ltd. Announces Highly Encouraging Oral PTH Market Survey Results
From GlobeNewswire News Releases
Entera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis
From GlobeNewswire News Releases
Introducing Investors to Hot Hi-Tech and Bio-tech Companies: Frost & Sullivan Releases Q1 Equity Research for Investors to Make Informed Decisions in 2020
Equity research is published in the framework of Frost & Sullivan's Independent Equity Research Program. This type of equity research is trusted by investors as it is unbiased and analysts have no... 
From PR Newswire
Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results
From GlobeNewswire News Releases
Entera Bio to Report Interim Data From EB613 Phase 2 Trial and First Quarter 2020 Business and Financial Results on May 21, 2020
Interim Three Month Top-line Biomarker Data Expected for the First 50% of Patients Enrolled in Phase 2 Osteoporosis Clinical Trial 
From GlobeNewswire News Releases
ENTERA BIO LTD ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2019
From GlobeNewswire News Releases
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.